Results 11 to 20 of about 2,626 (203)

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study. [PDF]

Int J Dermatol
Background: Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD).
Potestio L, Patruno C, Del Gaudio M, Ortoncelli M, Ribero S, Barei F, Ferrucci SM, Bonzano L, Trave I, Guanti MB, Gurioli C, Piraccini BM, Gori N, Ippoliti E, Peris K, Grigolato L, Rossi M, Foti C, Romita P, Tirone B, Nettis E, Esposito M, Fargnoli MC, Magnanimi LM, Pezzolo E, Hansel K, Stingeni L, Satta R, Mariano M, Pigliacelli F, Margiotta FM, Romanelli M, Ingurgio RC, Costanzo A, Narcisi A, Corazza M, Antiga E, Morrone P, Rubegni P, Calabrese L, Lazzeri L, Rubegni G, Guarneri F, Zerbinati N, Carugno A, Puca RV, Sarno O, Marasca C, Martina E, di Vico F, Napolitano M.   +50 more
europepmc   +4 more sources

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals [PDF]

Journal of Dermatological Treatment
Background Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient’s quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the ...
Giovanni Paolino, Alessandra Narcisi, Andrea Carugno, Piergiorgio Malagoli, Matteo R. Di Nicola, Antonio Foti, Vittoria G. Bianchi, Andrea Gustavo Locatelli, Paolo Sena, Antonio Costanzo, Santo R. Mercuri, Mario Valenti   +11 more
doaj   +6 more sources

Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab? [PDF]

Dermatology and Therapy
Introduction Tralokinumab, a human IgG4 monoclonal antibody that inhibits the IL-13 pathway, is approved for the treatment of atopic dermatitis. However, real-world data are lacking and are needed to inform its efficacy and safety in broader populations.
Neenu Sebastian, Omar Chircop, Tim H. Clayton, Firas C. Kreeshan, Hamish J. A. Hunter, Richard B. Warren   +5 more
doaj   +2 more sources

Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16 [PDF]

Dermatology and Therapy
Introduction Investigator’s Global Assessment (IGA) of clear/almost clear (0/1) skin is a high standard to achieve after 16 weeks of treatment for patients with moderate-to-severe atopic dermatitis (AD) and does not capture clinically meaningful ...
Amy S. Paller, Andrew Blauvelt, Weily Soong, H. Chih-ho Hong, Marie L. A. Schuttelaar, Shannon K. R. Schneider, Eric L. Simpson   +6 more
doaj   +2 more sources

The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma [PDF]

Frontiers in Pharmacology, 2019
Approximately 5–10% of asthmatic patients worldwide suffer from severe asthma. Experimental and clinical studies have demonstrated that IL-13 is an important cytokine in chronic airways inflammation.
Giancarlo Marone, Giancarlo Marone, Francescopaolo Granata, Francescopaolo Granata, Valentina Pucino, Antonio Pecoraro, Enrico Heffler, Enrico Heffler, Stefania Loffredo, Stefania Loffredo, Stefania Loffredo, Guy W. Scadding, Gilda Varricchi, Gilda Varricchi, Gilda Varricchi   +14 more
doaj   +3 more sources

Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory disease requiring long-term management. Biologic therapies have emerged as systemic treatment options for AD, and real-world evidence (RWE) of their use is needed to inform optimal treatment ...
Adrian O. Rodriguez, Caid Sterling Smith
doaj   +2 more sources

Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis

Journal of Dermatological Treatment, 2023
Purpose: Although psoriasis and atopic dermatitis (AD) were for decades considered to be opposing diseases, it is now known that these skin conditions can coexist or even overlap in the same individual. Especially when using modern drugs with targeted IL
Galina Balakirski, Sven-Niklas Burmann, Silke C. Hofmann, Alexander Kreuter   +3 more
doaj   +3 more sources

Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data

Frontiers in Pharmacology
BackgroundTralokinumab, a humanized monoclonal antibody targeting interleukin-13, has been primarily used for the treatment of moderate-to-severe atopic dermatitis.
Kaidi Zhao, Yang Zhao, Shengxiang Xiao, Chen Tu   +3 more
exaly   +3 more sources

Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies [PDF]

Antibodies
Background: Head and neck dermatitis (HND) represents a challenging phenotype of atopic dermatitis (AD), often showing suboptimal response or paradoxical worsening during biologic therapy.
Giuseppe Lauletta, Cataldo Patruno, Claudio Brescia, Andrea Cosenza, Carolina D’Elia, Valentina Ventura, Emanuela Martina, Maddalena Napolitano   +7 more
doaj   +2 more sources

Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis. [PDF]

Dermatol Ther (Heidelb)
Lebrikizumab is a novel mono- clonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe AD ...
Antonazzo IC, Girolomoni G, Patruno C, Langella R, Ottobrino V, Mantovani LG, Cortesi PA.   +6 more
europepmc   +3 more sources